AlphaCrest Capital Management LLC grew its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) by 1.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 34,900 shares of the life sciences company’s stock after purchasing an additional 457 shares during the quarter. AlphaCrest Capital Management LLC’s holdings in Integra LifeSciences were worth $1,886,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of the stock. Steward Partners Investment Advisory LLC raised its stake in Integra LifeSciences by 73.7% during the first quarter. Steward Partners Investment Advisory LLC now owns 707 shares of the life sciences company’s stock valued at $45,000 after buying an additional 300 shares in the last quarter. First Horizon Advisors Inc. acquired a new stake in shares of Integra LifeSciences during the 2nd quarter valued at approximately $54,000. Covestor Ltd lifted its stake in Integra LifeSciences by 63.0% during the first quarter. Covestor Ltd now owns 1,558 shares of the life sciences company’s stock worth $100,000 after purchasing an additional 602 shares during the last quarter. Captrust Financial Advisors boosted its holdings in Integra LifeSciences by 95.0% in the first quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock worth $129,000 after purchasing an additional 976 shares during the period. Finally, Inspire Investing LLC increased its stake in Integra LifeSciences by 6.9% during the second quarter. Inspire Investing LLC now owns 3,890 shares of the life sciences company’s stock valued at $210,000 after purchasing an additional 252 shares during the last quarter. Institutional investors own 87.33% of the company’s stock.
Analysts Set New Price Targets
IART has been the subject of several research reports. Piper Sandler decreased their price target on shares of Integra LifeSciences from $55.00 to $50.00 in a report on Wednesday, August 24th. Morgan Stanley increased their price target on Integra LifeSciences from $49.00 to $50.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 27th. Truist Financial reduced their price objective on Integra LifeSciences from $60.00 to $46.00 and set a “hold” rating for the company in a research report on Monday, October 17th. StockNews.com initiated coverage on Integra LifeSciences in a research report on Wednesday, October 12th. They issued a “buy” rating on the stock. Finally, Jefferies Financial Group began coverage on Integra LifeSciences in a research note on Tuesday, October 11th. They issued a “hold” rating and a $48.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $57.38.
Integra LifeSciences Stock Down 0.4 %
Integra LifeSciences Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.
- Get a free copy of the StockNews.com research report on Integra LifeSciences (IART)
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.